Purpose To study characteristics of patients with community-acquired complicated urinary
tract infections (cUTIs) and to compare effectiveness and antibiotic cost of treatment with …

The increasing global prevalence of carbapenem-resistant Enterobacteriaceae (CRE)
combined with the decline in effective therapies is a public health care crisis. After …

The aim of this study was to investigate the urinary bactericidal titers (UBTs) and 24-h area
under the UBT-versus-time curve (AUBT) of intravenous doripenem (500 mg every 8 h …

On August 29, 2017, the United States Food and Drug Administration (FDA) approved
meropenem/vaborbactam fixed combination for the treatment of adults with complicated …

Urinary tract infections, including cystitis, acute pyelonephritis, and prostatitis, are among the
most common diagnoses prompting antibiotic prescribing. The rise in antimicrobial …

Background Limited data are available to guide effective antibiotic durations for hospitalized
patients with complicated urinary tract infections (cUTIs). Methods We conducted an …

Background As one of the most common indications for antimicrobial prescription in the
community, the management of urinary tract infections (UTIs) is both complicated by, and a …

A urinary tract infection (UTI) disease state management guideline, including risk-based
antimicrobial recommendations, Foley catheter management and transitions of care, was …

ABSTRACT Introduction: Meropenem/vaborbactam (M/V) represents the first carbapenem
and β-lactamase inhibitor combination approved for treatment of complicated urinary tract …

Introduction The addition of the β-lactamase inhibitor relebactam to imipenem restores the
antibacterial activity against the majority of multidrug resistant Gram-negative bacteria …